Lipid Nanoparticles (LNP) Market size was valued at USD 627.9 million in 2021 and is poised to grow at a significant CAGR of 7.5% over 2022–2028. Nanoparticles have received interest recently because of their potential role in efficient medication delivery. LNPs are now widely recognized in the pharmaceutical and biotechnology sectors as a cutting-edge, commercially successful delivery system enabling the unheard-of commercialization of gene treatments. As a result, LNPs have ushered in a new era of medicine that allows for the effective treatment or cure of genetic illnesses and the production of vaccines within the body rather than through the purification of non-infectious viruses. For the creation of therapeutic products for protein replacement therapy, preventive or curative vaccinations, and gene editing, LNP-based formulations provide significant prospects. LNP-based formulations are increasingly being considered for use across a variety of other application areas, including anticancer agents and antibiotics, peptide and protein-based synthetic vaccines, ligand targeted formulations, and imaging contrast agents, in addition to RNA, DNA, and siRNA-based therapeutics. LNPs are anticipated to facilitate the creation of ever more sophisticated nanomedicines during the next ten years. Examples include the design of synthetic vaccines, immunotherapies, and drug combination products when LNP-based formulations are necessary to guarantee the co-presentation of various components into the target cell. Personalized or custom formulations that can enable results like the insertion of tumor-associated neoantigens into mRNA vaccines are another opportunity that can be achieved by combining LNPs with tissue sequencing and other valuable technologies.
Recent Market Developments:
In February 2021, Merck announced the extension of its strategic partnership with BioNTech to accelerate the supply of urgently needed lipids and increase the quantities to be delivered in 2021. The lipids were used for the production of the Pfizer-BioNTech Covid-19 vaccine.